Balance Sheet
Cash Flow Statement
Capital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Account PayablesChange in Account PayablesChange in Accured ExpensesChange in Accured ExpensesChange in CashChange in InventoryChange in InventoryChange in ReceivablesChange in ReceivablesDepreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and DepletionDepreciation and DepletionExchange Rate EffectExchange Rate EffectFree Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesNet Cash FlowNet Cash FlowNet IncomeNon-cash ItemsNon-cash ItemsOther Working Capital ChangesOther Working Capital ChangesShare-based CompensationShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Adagio Medical Holdings (ADGM) Cash from Investing Activities (2023 - 2026)

Adagio Medical Holdings (ADGM) reported Cash from Investing Activities of -$2000.0 for Q1 2026, up 99.4% year-over-year from -$1003.0 in Q1 2025, and down 100.41% on a QoQ basis from $491000.0 in Q4 2025.

Adagio Medical Holdings (ADGM) has 4 years of Cash from Investing Activities data on file, last reported at -$2000.0 in Q1 2026.

  • Quarterly Cash from Investing Activities rose 99.4% year-over-year to -$2000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$424000.0 (up 60.63% YoY) and the FY2025 annual result came in at -$374000.0, up 70.78% from the prior year.
  • Cash from Investing Activities retreated to -$2000.0 in Q1 2026 per ADGM's latest filing, from $491000.0 in the prior quarter.
  • Across five years, Cash from Investing Activities topped out at $491000.0 in Q4 2025 and bottomed at -$578000.0 in Q3 2024.
  • The 4-year median for Cash from Investing Activities is -$20000.0 (2023), against an average of -$86857.1.
  • The widest annual swing landed in 2025, when Cash from Investing Activities tumbled 106.79%; it then jumped 99.4% in 2026.
  • Tracing ADGM's Cash from Investing Activities over 4 years: stood at -$20000.0 in 2023, then sank by 2790.0% to -$578000.0 in 2024, then soared by 184.95% to $491000.0 in 2025, then plunged by 100.41% to -$2000.0 in 2026.
  • Per Business Quant, the three latest ADGM Cash from Investing Activities figures stand at -$2000.0 (Q1 2026), $491000.0 (Q4 2025), and -$335000.0 (Q1 2025).

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Cash from Investing Activities (Qtr)
1 Abbott Laboratories 152.82 Bn 146.17 Bn 6.27 Bn -20.32 Bn
2 Stryker 115.07 Bn 112.19 Bn 3.81 Bn -185.00 Mn
3 Medtronic 95.25 Bn 87.08 Bn 5.76 Bn -816.00 Mn
4 Boston Scientific 71.38 Bn 70.17 Bn 3.61 Bn -591.00 Mn
5 Edwards Lifesciences 51.08 Bn 47.41 Bn 1.29 Bn -92.80 Mn
6 Koninklijke Philips 29.38 Bn 26.07 Bn 2.07 Bn -475.32 Mn
7 Dexcom 28.84 Bn 27.72 Bn 750.30 Mn -298.50 Mn
8 GE HealthCare Technologies 28.56 Bn 26.49 Bn 1.98 Bn -2.50 Bn
9 Steris 20.71 Bn 20.30 Bn 697.10 Mn -217.20 Mn
10 Adagio Medical Holdings 16.86 Mn 3.95 Mn - -2,000.00

Historic Data

Download Data 🔒
DateValue
Mar 31, 2026 -2,000.00
Mar 31, 2026 -2,000.00
Dec 31, 2025 491,000.00
Dec 31, 2025 491,000.00
Mar 31, 2025 -335,000.00
Mar 31, 2025 -335,000.00
Sep 30, 2024 -578,000.00
Sep 30, 2024 -578,000.00
Jun 30, 2024 -2,000.00
Jun 30, 2024 -2,000.00
Mar 31, 2024 -162,000.00
Mar 31, 2024 -162,000.00
Dec 31, 2023 -20,000.00
Dec 31, 2023 -20,000.00